Home > mAChR & mAChR & > Oxybutynin

Oxybutynin

奥昔布宁

Oxybutynin 是一种抗胆碱药，用于减少尿量，减轻膀胱负担。

目录号
EY0947
EY0947
纯度
99.23%
99.23%
规格
100 mg
500 mg
原价
520
990
售价
520
990
库存
现货
现货
订购
订购
订购
订购
订购
订购
具体折扣请咨询客服

  • 生物活性

    Oxybutynin is a competitive antagonist of the M1, M2, and M3 subtypes of the muscarinic acetylcholine receptor, used to relieve urinary and bladder difficulties.

  • 体外研究

  • 体内研究

  • 激酶实验

  • 细胞实验

  • 动物实验

  • 不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数


    例如，已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法：将88 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到该药物用于大鼠的等效剂量44 mg/kg。

  • 参考文献

    [1] Lukkari E, et al. Pharmacol Toxicol, 1998, 82(4), 161-166.

    分子式
    C22H31NO3    		 分子量
    357.49    		 CAS号
    5633-20-5    		 储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂（常温）
    		 DMSO
    72 mg/mL    		 Water
    <1 mg/mL    		 Ethanol
    72 mg/mL

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT Number Conditions Interventions Sponsor/Collaborators Phases Start Date Last Updated
    NCT01310712 Hyperhidrosis Drug: Oxybutynin|Drug: placebo University of Sao Paulo Phase 4 2010-12-01 2011-09-21
    NCT01855256 Hyperhidrosis Drug: Oxybutynin|Drug: Placebo University Hospital, Brest|Ministry of Health, France Phase 3 2013-06-01 2014-07-07
    NCT02538302 Nocturnal Enuresis Drug: Minirin|Drug: Oxybutynin Hormozgan University of Medical Sciences Phase 3 2013-07-01 2015-08-29
    NCT01328015 Hyperhidrosis Drug: Oxybutynin 5 mg pills Federal University of So Paulo Phase 2 2010-03-01 2011-04-01
    NCT02633371 Hyperhidrosis Drug: Oxybutynin 3% gel University of Colorado, Denver|Society for Pediatric Dermatology 2016-02-01 2017-02-13
    NCT01192568 Overactive Detrusor|Neurogenic Bladder Drug: Oxybutynin Watson Pharmaceuticals Phase 4 2011-05-01 2016-12-13
    NCT02327936 Overactive Bladder Drug: Fesoterodine|Drug: Oxybutynin XL Stphane Bolduc|Pfizer|Centre Hospitalier Universitaire de Qubec, CHU de Qubec Phase 3 2014-12-01 2016-12-17
    NCT02099695 Hyperhidrosis Drug: Oxybutynin|Drug: Placebo Cristlia Produtos Qumicos Farmacuticos Ltda.|Hospital Israelita Albert Einstein|University of Sao Paulo Phase 3 2015-12-01 2016-07-25
    NCT00909181 Urge Urinary Incontinence|Urinary Frequency Drug: Oxybutynin|Drug: Placebo Antares Pharma Inc. Phase 3 2009-03-01 2014-06-23
    NCT01118429 Axillary Hyperhidrosis|Osmidrosis Drug: Oxybutynin|Drug: Placebo Grupo de Cirurgia Vascular 2007-01-01 2010-05-05
    NCT00613327 Urinary Bladder, Overactive Drug: Oxybutynin chloride OROS Janssen Korea, Ltd., Korea Phase 4 2007-09-01 2013-10-24
    NCT02908529 Obstructive Sleep Apnea (OSA) Drug: Combination of Atomoxetine and Oxybutynin|Drug: Placebo, 2 tablets Brigham and Women's Hospital Phase 1|Phase 2 2016-09-01 2017-02-21
    NCT00224029 Detrusor Hyperreflexia Drug: Oxybutynin transdermal system Watson Pharmaceuticals Phase 4 2004-12-01 2010-04-07
    NCT00224016 Detrusor Hyperreflexia Drug: Oxybutynin|Drug: Oxybutynin Watson Pharmaceuticals Phase 4 2004-12-01 2012-02-07
    NCT01050114 Overactive Bladder Drug: onaBoNT-A|Drug: Oxybutynin ER Christopher Patrick Smith|Baylor College of Medicine Phase 3 2013-08-01 2016-08-29
    NCT01423838 Overactive Bladder Drug: Solifenacin|Drug: Oxybutynin Adana Numune Training and Research Hospital|Kocaeli University|Akdeniz University|Cukurova University|Baskent University|Ankara University|University of Gaziantep|Inonu University|Gaziosmanpasa University|Kahramanmaras Sutcu Imam University Phase 4 2011-09-01 2011-08-25
    NCT01796548 Detrusor Function, Overactive Drug: Oxybutinin Extended-Release Janssen-Cilag Ltd.,Thailand Phase 4 2008-12-01 2013-10-31
    NCT00170768 Healthy Volunteers Drug: Darifenacin|Drug: Oxybutynin|Drug: Placebo Novartis Phase 2 2005-02-01 2008-01-18
    NCT02973659 Hyperhidrosis Drug: Oxybutynin|Drug: Placebos Tel-Aviv Sourasky Medical Center 2015-05-01 2016-11-23
    NCT00431041 Overactive Bladder Drug: solifenacin|Drug: oxybutynin immediate release Astellas Pharma Inc|Astellas Pharma Canada, Inc. Phase 4 2006-12-01 2010-06-01

    注：以上所有数据均来自公开文献，并不保证对所有实验均有效，数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 ：
  • 收件地址 ：
  • 电话号码 ：
  • 单位名称 ：
  • 产品货号 ：
  • 产品规格 ：
  • 发票抬头以及单位税号 ：